	US 12,258,329 B2
	Pyrimidone derivatives as selective cytotoxic agents against HIV infected cells
Antonella Converso, Elkins Park, PA (US); and Cheng Wang, Fort Washington, PA (US)
Assigned to Merck Sharp & Dohme LLC, Rahway, NJ (US)
Appl. No. 17/413,882
Filed by Merck Sharp & Dohme LLC, Rahway, NJ (US)
PCT Filed Dec. 13, 2019, PCT No. PCT/US2019/066125 § 371(c)(1), (2) Date Jun. 14, 2021, PCT Pub. No. WO2020/131597, PCT Pub. Date Jun. 25, 2020.
Claims priority of provisional application 62/781,356, filed on Dec. 18, 2018.
Prior Publication US 2022/0064147 A1, Mar. 3, 2022
Int. Cl. C07D 239/52 (2006.01); A61K 31/505 (2006.01); A61K 45/06 (2006.01); A61P 31/18 (2006.01); C07D 403/06 (2006.01)

CPC C07D 403/06 (2013.01) [A61K 45/06 (2013.01)]

9 Claims

1. A compound which is:

5-(difluoromethyl)-2-methyl-3((1-((2-methyl-6-oxo-1,6-dihydropyrimidin-5-yl)methyl)-6-oxo-4-(perfluoroethyl)-1,6-dihydropyrimidin-5-yl)oxy)benzonitrile;

or a pharmaceutically acceptable salt thereof.